{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:37:31Z","timestamp":1790667451857,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7541","license":[{"start":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T00:00:00Z","timestamp":1423440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T00:00:00Z","timestamp":1423440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2015,3,5]]},"DOI":"10.1038\/nature14119","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T18:15:08Z","timestamp":1423592108000},"page":"102-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation"],"prefix":"10.1038","volume":"519","author":[{"given":"Tea","family":"Pemovska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen A.","family":"Repasky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciar\u00e1n N.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"McTigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brion W.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,9]]},"reference":[{"key":"BFnature14119_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","volume":"138","author":"R Kurzrock","year":"2003","unstructured":"Kurzrock, R., Kantarjian, H. M., Druker, B. J. & Talpaz, M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819\u2013830 (2003)","journal-title":"Ann. Intern. Med."},{"key":"BFnature14119_CR2","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640\u20132653 (2005)","journal-title":"Blood"},{"key":"BFnature14119_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006)","journal-title":"N. Engl. J. Med."},{"key":"BFnature14119_CR4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus, A. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303\u20132309 (2007)","journal-title":"Blood"},{"key":"BFnature14119_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054\u20131061 (2009)","journal-title":"Leukemia"},{"key":"BFnature14119_CR6","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472\u20133475 (2002)","journal-title":"Blood"},{"key":"BFnature14119_CR7","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen, H. A. et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332\u20132338 (2006)","journal-title":"Blood"},{"key":"BFnature14119_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli, S. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J. Clin. Oncol. 27, 469\u2013471 (2009)","journal-title":"J. Clin. Oncol."},{"key":"BFnature14119_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nbt0114-9b","volume":"32","author":"M Senior","year":"2014","unstructured":"Senior, M. FDA halts then allows sales of Ariad\u2019s leukemia medication. Nature Biotechnol. 32, 9\u201311 (2014)","journal-title":"Nature Biotechnol."},{"key":"BFnature14119_CR10","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1073\/pnas.1321173111","volume":"111","author":"DL Gibbons","year":"2014","unstructured":"Gibbons, D. L. et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc. Natl Acad. Sci. USA 111, 3550\u20133555 (2014)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature14119_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie, M. S. et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26, 428\u2013442 (2014)","journal-title":"Cancer Cell"},{"key":"BFnature14119_CR12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416\u20131429 (2013)","journal-title":"Cancer Discov."},{"key":"BFnature14119_CR13","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014)","journal-title":"Sci. Rep."},{"key":"BFnature14119_CR14","doi-asserted-by":"publisher","first-page":"18281","DOI":"10.1073\/pnas.1207759109","volume":"109","author":"M McTigue","year":"2012","unstructured":"McTigue, M. et al. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc. Natl Acad. Sci. USA 109, 18281\u201318289 (2012)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature14119_CR15","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931\u20131939 (2011)","journal-title":"Lancet"},{"key":"BFnature14119_CR16","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1021\/bi900522y","volume":"48","author":"J Solowiej","year":"2009","unstructured":"Solowiej, J. et al. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 48, 7019\u20137031 (2009)","journal-title":"Biochemistry"},{"key":"BFnature14119_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J. & Daley, G. Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Struct. Mol. Biol. 15, 1109\u20131118 (2008)","journal-title":"Nature Struct. Mol. Biol."},{"key":"BFnature14119_CR18","doi-asserted-by":"publisher","first-page":"e1000487","DOI":"10.1371\/journal.pcbi.1000487","volume":"5","author":"A Dixit","year":"2009","unstructured":"Dixit, A. & Verkhivker, G. M. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLOS Comput. Biol. 5, e1000487 (2009)","journal-title":"PLOS Comput. Biol."},{"key":"BFnature14119_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou, T. et al. Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 77, 1\u201311 (2011)","journal-title":"Chem. Biol. Drug Des."},{"key":"BFnature14119_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401\u2013412 (2009)","journal-title":"Cancer Cell"},{"key":"BFnature14119_CR21","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","volume":"111","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz, A. et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111, 4355\u20134364 (2008)","journal-title":"Blood"},{"key":"BFnature14119_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","volume":"19","author":"WW Chan","year":"2011","unstructured":"Chan, W. W. et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19, 556\u2013568 (2011)","journal-title":"Cancer Cell"},{"key":"BFnature14119_CR23","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnol. 29, 1046\u20131051 (2011)","journal-title":"Nature Biotechnol."},{"key":"BFnature14119_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4137\/CMO.S10594","volume":"7","author":"M Gross-Goupil","year":"2013","unstructured":"Gross-Goupil, M., Francois, L., Quivy, A. & Ravaud, A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin. Med. Insights Oncol. 7, 269\u2013277 (2013)","journal-title":"Clin. Med. Insights Oncol."},{"key":"BFnature14119_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/14740338.2014.888413","volume":"13","author":"S Bracarda","year":"2014","unstructured":"Bracarda, S. et al. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin. Drug Saf. 13, 497\u2013510 (2014)","journal-title":"Expert Opin. Drug Saf."},{"key":"BFnature14119_CR26","first-page":"107","volume":"7","author":"E Verzoni","year":"2014","unstructured":"Verzoni, E. et al. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics. Pers. Med. 7, 107\u2013116 (2014)","journal-title":"Pharmgenomics. Pers. Med."},{"key":"BFnature14119_CR27","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/FTD.0b013e318292b931","volume":"35","author":"DH Josephs","year":"2013","unstructured":"Josephs, D. H., Fisher, D. S., Spicer, J. & Flanagan, R. J. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther. Drug Monit. 35, 562\u2013587 (2013)","journal-title":"Ther. Drug Monit."},{"key":"BFnature14119_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","volume":"52","author":"Y Chen","year":"2013","unstructured":"Chen, Y. et al. Clinical pharmacology of axitinib. Clin. Pharmacokinet. 52, 713\u2013725 (2013)","journal-title":"Clin. Pharmacokinet."},{"key":"BFnature14119_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"NP Shah","year":"2008","unstructured":"Shah, N. P. et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485\u2013493 (2008)","journal-title":"Cancer Cell"},{"key":"BFnature14119_CR30","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-12-3904","volume":"73","author":"T O'Hare","year":"2013","unstructured":"O'Hare, T. et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res. 73, 3356\u20133370 (2013)","journal-title":"Cancer Res."},{"key":"BFnature14119_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0005-2744(69)90420-3","volume":"185","author":"JF Morrison","year":"1969","unstructured":"Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269\u2013286 (1969)","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnature14119_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/protein\/14.12.993","volume":"14","author":"RB Kapust","year":"2001","unstructured":"Kapust, R. B. et al. Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng. 14, 993\u20131000 (2001)","journal-title":"Protein Eng."},{"key":"BFnature14119_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007)","journal-title":"J. Appl. Crystallogr."},{"key":"BFnature14119_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010)","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"BFnature14119_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240\u2013255 (1997)","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"BFnature14119_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010)","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"BFnature14119_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"91","author":"P le Coutre","year":"1999","unstructured":"le Coutre, P. et al. In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163\u2013168 (1999)","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnature14119_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/cb400040z","volume":"8","author":"J Solowiej","year":"2013","unstructured":"Solowiej, J., Chen, J. H., Zou, H. Y., Grant, S. K. & Murray, B. W. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain. ACS Chem. Biol. 8, 978\u2013986 (2013)","journal-title":"ACS Chem. Biol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature14119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature14119","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature14119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:28:19Z","timestamp":1684434499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature14119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,9]]},"references-count":38,"journal-issue":{"issue":"7541","published-print":{"date-parts":[[2015,3,5]]}},"alternative-id":["BFnature14119"],"URL":"https:\/\/doi.org\/10.1038\/nature14119","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,9]]},"assertion":[{"value":"17 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.W.M., P.W., C.N.C., M.M. and E.J. are all Pfizer employees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}